Hepatocellular carcinoma (HCC) is one of the male-dominant liver diseases with poor
prognosis, although treatments for HCC have been progressing in the past decades …

Previous studies have indicated that males are at a higher risk of developing hepatocellular
carcinoma (HCC) compared with females. Identifying the factors that cause this gender …

Background & Aims: Androgen effects on hepatocellular carcinoma (HCC) remain
controversial and androgen ablation therapy to treat HCC also leads to inconsistent results …

Androgen/androgen receptor (AR) signaling plays important roles in normal liver function
and in progression of liver diseases. In studies of noncancerous liver diseases, AR knockout …

Hepatocellular carcinoma (HCC) is a male-dominant disease with poor prognosis. Sorafenib
is the only approved systemic chemotherapeutic drug for patients with advanced HCC …

Hepatocellular carcinoma (HCC) is a male‐dominant cancer, and androgen receptor (AR)
has been linked to the pathogenesis of HCC. However, AR expression and its precise role in …

Androgen receptor (AR) activity is associated with cancer development and progression. In
hepatocellular carcinoma (HCC), AR contributes to HCC incidence, but the role of AR in …

Early reports suggested androgen/androgen receptor (AR) signals promote
hepatocarcinogenesis. However, all antiandrogen clinical trials failed in advanced …

Hepatocellular carcinoma (HCC) is the predominant type of liver cancer and a leading
cause of cancer-related death globally. It is also a sexually dimorphic disease with a male …

BACKGROUND: Androgen receptors (ARs) act as transcription factors. An increased AR
activity could be due either to mutations or to an increased expression of the receptor. AR …